The optimal timing for percutaneous coronary intervention (PCI) in patients undergoing transcatheter aortic valve replacement (TAVR) is debatable. Leveraging the STS/ACC TVT Registry and Medicare linkage, we analyzed patients with stable coronary disease undergoing PCI and TAVR (within 90 days of each other) between 2015 and 2023 using contemporary balloon expandable bioprosthesis. A total of 49,344 patients undergoing PCI before (84.7%), after (1.3%) or concomitantly (14%) with TAVR were included in this analysis. In a propensity-matched analysis, composite of all-cause mortality and stroke were similar in 3 groups at 3 years of follow up. However, due to small numbers of patients undergoing PCIs after the TAVR, while comparing the other two groups, event rates were significantly lower in patients undergoing PCI before TAVR as compared with concomitant PCI with TAVR at 3 years (p = 0.002). In patients with stable CAD undergoing TAVR, there is no difference in outcomes at three years amongst three groups.View Large Image Figure ViewerDownload Hi-res image Download (PPT)
No takes yet. Share an insight, caveat, or question.
Dhoble et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: